Efficacy of Ramelteon in pharmacoresistant patients with Dravet syndrome aged more than 6 years in the pediatric epileptic centers in seizures control

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220105053639N1

Enrollment

Registered

2022-04-19

Start date

2022-04-30

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dravet Syndrome. Polymorphic epilepsy in infancy (PMEI)

Interventions

Intervention group: Ten patients with Dravet syndrom with Ramelteon treatment by the dose of 8 mg/day orally divided into two parts for three months.

Eligibility

Sex/Gender

All

Age

6 Years to No maximum

Inclusion criteria

Inclusion criteria: Minimum seizure frequency should be 6 seizures per month Minimum age should be 6 years old

Exclusion criteria

Exclusion criteria: If the patient can not swallow the tablet.

Design outcomes

Primary

Measure	Time frame
Seizure frequency. Timepoint: Measurement of seizure frequency one month before the study (before the intervention) and 1, 2 and 3 months after the start of Remeltion treatment. Method of measurement: Questionnaire.	—

Secondary

Measure	Time frame
Any outcome other than reducing the frequency of seizures and improving the quality of treatment (side effect) is considered a secondary consequence. Timepoint: Measurement of seizure frequency one month before the study (before the intervention) and 1, 2 and 3 months after the start of Remeltion. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSareh Hosseinpour

Tehran University of Medical Sciences

hosseinpour.sare@gmail.com+98 21 6693 0024

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026